InvestSMART

Clarity Pharmaceuticals Ltd (ASX: CU6) - Announcements

Current share price for CU6 : $2.180 0.08 (3.81%)+

ASX company news and announcements for Clarity Pharmaceuticals Ltd (CU6) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clarity Pharmaceuticals Ltd (CU6) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clarity Pharmaceuticals Ltd (CU6), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clarity Pharmaceuticals Ltd (CU6)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$813 Theranostic prostate cancer trial advances to multi-dose 15 Mar 2024 10:45AM $2.650 $2.180 fallen by 17.74%
$813 Additional COBRA trial data results 6 Mar 2024 9:57AM $2.880 $2.180 fallen by 24.31%
$813 S&P DJI Announces March 2024 Quarterly Rebalance 1 Mar 2024 5:03PM $2.690 $2.180 fallen by 18.96%
$813 Correction to 2023 Annual Report 29 Feb 2024 3:11PM $2.900 $2.180 fallen by 24.83%
$813 Half Yearly Report and Accounts 29 Feb 2024 3:06PM $2.900 $2.180 fallen by 24.83%
$813 Appendix 4D 29 Feb 2024 2:57PM $2.900 $2.180 fallen by 24.83%
$813 Cleansing Notice 15 Feb 2024 6:19PM $2.780 $2.180 fallen by 21.58%
$813 Application for quotation of securities - CU6 15 Feb 2024 6:10PM $2.780 $2.180 fallen by 21.58%
$813 Initial COBRA results 15 Feb 2024 9:49AM $2.740 $2.180 fallen by 20.44%
$813 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2024 4:15PM $2.350 $2.180 fallen by 7.23%
$813 Cleansing Notice 19 Jan 2024 4:25PM $2.350 $2.180 fallen by 7.23%
$813 Application for quotation of securities - CU6 19 Jan 2024 4:22PM $2.350 $2.180 fallen by 7.23%
$813 Application for quotation of securities - CU6 19 Jan 2024 4:19PM $2.350 $2.180 fallen by 7.23%
$813 Final Director's Interest Notice 16 Jan 2024 9:55AM $2.200 $2.180 fallen by 0.91%
$813 Resignation of Non-Executive Directors 16 Jan 2024 9:16AM $2.200 $2.180 fallen by 0.91%
$813 Notification of cessation of securities - CU6 9 Jan 2024 2:42PM $2.170 $2.180 risen by 0.46%
$813 First patient dosed in Phase III prostate cancer trial 22 Dec 2023 9:53AM $1.775 $2.180 risen by 22.82%
$813 Recruitment closes for a diagnostic Phase II trial in NETs 19 Dec 2023 9:37AM $1.650 $2.180 risen by 32.12%
$813 Change of Director's Interest Notice - Taylor 14 Dec 2023 9:22AM $1.705 $2.180 risen by 27.86%
$813 Change of Director's Interest Notice - Biggin 14 Dec 2023 9:21AM $1.705 $2.180 risen by 27.86%
$813 Notification regarding unquoted securities - CU6 13 Dec 2023 9:14AM $1.690 $2.180 risen by 28.99%
$813 Cleansing Notice 1 Dec 2023 5:31PM $1.360 $2.180 risen by 60.29%
$813 Application for quotation of securities - CU6 1 Dec 2023 5:26PM $1.360 $2.180 risen by 60.29%
$813 Ceasing to be a substantial holder 30 Nov 2023 3:20PM $1.470 $2.180 risen by 48.30%
$813 Phase III CLARIFY trial in prostate cancer commences 30 Nov 2023 9:50AM $1.300 $2.180 risen by 67.69%

276 - 300 of 511 results

Page 12 of 21

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.